- Home
- WST vs EQR Comparison
WST vs EQR Comparison
Compare WST & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WST
- EQR
- Stock Information
- Founded
- WST 1923
- EQR 1993
- Country
- WST United States
- EQR United States
- Employees
- WST N/A
- EQR N/A
- Industry
- WST Medical/Dental Instruments
- EQR Real Estate Investment Trusts
- Sector
- WST Health Care
- EQR Real Estate
- Exchange
- WST Nasdaq
- EQR Nasdaq
- Market Cap
- WST 23.2B
- EQR 26.4B
- IPO Year
- WST N/A
- EQR 1993
- Fundamental
- Price
- WST $333.19
- EQR $72.37
- Analyst Decision
- WST Strong Buy
- EQR Buy
- Analyst Count
- WST 5
- EQR 19
- Target Price
- WST $437.75
- EQR $76.61
- AVG Volume (30 Days)
- WST 482.3K
- EQR 1.4M
- Earning Date
- WST 02-13-2025
- EQR 01-28-2025
- Dividend Yield
- WST 0.25%
- EQR 3.73%
- EPS Growth
- WST N/A
- EQR 35.67
- EPS
- WST 6.74
- EQR 2.44
- Revenue
- WST $2,876,400,000.00
- EQR $2,940,829,000.00
- Revenue This Year
- WST N/A
- EQR N/A
- Revenue Next Year
- WST $6.08
- EQR $4.04
- P/E Ratio
- WST $49.37
- EQR $29.70
- Revenue Growth
- WST N/A
- EQR 3.33
- 52 Week Low
- WST $265.00
- EQR $57.33
- 52 Week High
- WST $413.70
- EQR $78.83
- Technical
- Relative Strength Index (RSI)
- WST 58.32
- EQR 47.25
- Support Level
- WST $325.33
- EQR $69.35
- Resistance Level
- WST $335.53
- EQR $72.12
- Average True Range (ATR)
- WST 7.63
- EQR 1.35
- MACD
- WST 0.36
- EQR -0.13
- Stochastic Oscillator
- WST 76.56
- EQR 61.31
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 299 apartment communities with around 80,000 units and is developing three additional properties with 977 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.